LUTHERVILLE, Md., Oct. 21, 2014 /PRNewswire/ -- The National Association of Drug Diversion Investigators, also known as NADDI, facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion for the purposes of meth manufacturing, is pleased with the latest National Precursor Log Exchange (NPLEx) results.
The NPLEx system, created by Appriss, Inc., reported January through September, third quarter results (http://www.appriss.com/nplexstats), for the tracking and blocking of illegal sales of pseudoephedrine and ephedrine medication (PSE/EPH).
Overall, there is a continued downward trend of fewer grams tracked and blocked and also fewer people buying over-the-counter PSE/EPH medication.
The breakdown by state in the report shows the total number of boxes reported as purchased, the total number of grams reported as purchased, the total number of boxes and grams that were blocked based on state and federal laws, and the total number of unique individuals reported as purchasing over-the-counter PSE/EPH.
NADDI Executive Director Charles Cichon states that, "NPLEx is showing impressive results through Q3 2014. The technology is invaluable and not only allows pharmacists to block illegal purchases of medications containing pseudoephedrine at the counter, but it also protects law-abiding citizens' access to the medications they depend on for relief from cold and allergy symptoms. I am confident that NPLEx will continue to show a downward trend for key indicators that the fight against meth in our communities is working."
About NADDI and Public Safety
Established in 1989, the National Association of Drug Diversion Investigators, Inc. (NADDI) is a unique membership organization whose members are responsible for investigating and prosecuting pharmaceutical drug diversion. The organization has proven to be a valuable asset to law enforcement, the pharmaceutical industry and health regulatory personnel. NADDI's objective is simple: to improve the members' ability to investigate, and prosecute, pharmaceutical drug diversion. You can learn about NADDI here: www.NADDI.org
Logo - http://photos.prnewswire.com/prnh/20120208/CL50011LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nplex-continues-to-be-effective-in-the-fight-against-meth-420699644.html
SOURCE Appriss
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article